Τίτλος:
The Role of Macrolides for the Management of Community-Acquired
Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19):
A Position Paper by Four Medical Societies from Greece
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
In light of the accumulating evidence for survival benefit coming from
the use of macrolides for community-acquired pneumonia (CAP), a group of
experts from the field of internal medicine and infectious diseases
frame a position statement on the use of macrolides for the management
of bacterial CAP and for infection by the novel coronavirus (COVID-19).
The statement is framed taking into consideration existing publications
and own research experience. The main content of this statement is that
the combination of one beta-lactam and a macrolide should be the first
treatment of choice for patients with severe bacterial CAP. Severity is
assessed as scoring 2 or more points on the CURB65 scoring system of
severity or as pneumonia severity index III to V or C-reactive protein
more than 150 mg/l; the suggested macrolide is either azithromycin or
clarithromycin. The experts also suggest that in COVID-19 pneumonia, the
combination of one beta-lactam and a macrolide should be reserved only
when there is strong suspicion of bacterial co-infection.
Συγγραφείς:
Giamarellos-Bourboulis, Evangelos J.
Daikos, George L. and
Gargalianos, Panagiotis
Gogos, Charalambos
Lazanas, Marios and
Panagopoulos, Periklis
Poulakou, Garyphallia
Sambatakou, Helen
and Samarkos, Michael
Περιοδικό:
Infectious Diseases and Therapy
Εκδότης:
Springer-Verlag London Ltd
Λέξεις-κλειδιά:
Community-acquired pneumonia; COVID-19; Azithromycin; Clarithromycin;
Immunomodulation
DOI:
10.1007/s40121-021-00471-1
